Bosutinib a Src / Abl inhibitor kinasus tyrosinus dualis probatus ad tractationem periodi chronici nuper praecogniti (CP) chronici myelogenei leukemia (CML), vel resistens vel intolerans ad curationes praecedentes CML. Studium comparavit notitias ex curationibus primitivarum besutinib et imatinib ad ≥24 mensium sequentium. BFORE perennem, apertum Phase III Volumen studium cum summa 536 aegris ascriptum et passim assignatum ad recipiendum bursatinib (n = 268) vel imatinib (n = 268) in 1 1 ratione tractandi.
At a follow-up of 12 months, compared with the imatinib group, the bosutinib group showed higher molecular remission (MR) and complete cytogenetic remission (CCyR). XXIV Post menses differentia persequi intenderunt. In XXIV menses sequitur-usque, in duo major coetus ostendit in remissionem hypothetica (MMR) differentia, sed differentiae MR24 MR24 et non significans. Cum imatinib coetus ad MR, quo brevior CCyR bosutinib in elit. Sex aegris bosutinib in coetus et coetus septem imatinib in aegris qui conversi sunt ad accelerated / celeri tempus. In XXIV, mensibus sequantur eum, comparari cum imatinib coetus, quod coetus bosutinib ostendit altiorem major fit remissio hypothetica (MMR). Studies in primo-support usum bosutinib curatio recta CP CML aegris.
